Managed Care

New Hepatitis C drugs: A balancing act of costs and benefits

In the rapidly evolving market for hepatitis C virus treatments, much more effective medications with higher price tags will require careful cost-benefit analyses, says F. Randy Vogenberg, PhD, RPh.


Medical Devices Summit Boston, MA February 19–20, 2015
3rd Annual Summit to Improve Adherence and Enhance Patient Engagement Philadelphia, PA March 9–10, 2015
Value-Added Solutions for Enhanced Customer Experience Philadelphia, PA March 9, 2015